Log in

Relevant bibliographies by topics / Liquide biopsy / Journal articles

To see the other types of publications on this topic, follow the link: Liquide biopsy.

Journal articles on the topic 'Liquide biopsy'

Author: Grafiati

Published: 9 September 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Liquide biopsy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Singh, Pratibha, Meenakshi Gothwal, and Garima Yadav. "Liquid Biopsy in Ovarian Cancer." Indian Journal of Obstetrics and Gynecology 6, no. 4 (2018): 427–31. http://dx.doi.org/10.21088/ijog.2321.1636.6418.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Russo, Antonio, and Antonio Galvano. "Biopsia Líquida en Oncología: ¿Mito o Realidad?" Revista de la Facultad de Medicina Humana 20, no. 1 (January 15, 2020): 8–9. http://dx.doi.org/10.25176/rfmh.v20i1.2643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Khurshid, Zohaib, and Shahjahan Katpar. "Human Saliva as a Liquid Biopsy for Detecting the SARS-CoV-2." Journal of the Pakistan Dental Association 29, Special Supplement (July 24, 2020): S1—S3. http://dx.doi.org/10.25301/jpda.29s.s1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lavine, M. S. "Liquid Biopsy." Science 328, no. 5975 (April 8, 2010): 141. http://dx.doi.org/10.1126/science.328.5975.141-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gingras, Isabelle, Roberto Salgado, and Michail Ignatiadis. "Liquid biopsy." Current Opinion in Oncology 27, no. 6 (November 2015): 560–67. http://dx.doi.org/10.1097/cco.0000000000000223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Siddiqua, Umme Iffat. "Liquid Biopsy." KYAMC Journal 10, no. 1 (May 22, 2019): 1. http://dx.doi.org/10.3329/kyamcj.v10i1.41473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Goodwin, Peter M. "Liquid Biopsy." Oncology Times 38, no. 13 (July 2016): 40. http://dx.doi.org/10.1097/01.cot.0000489521.34002.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fulmer, Tim. "Liquid biopsy." Science-Business eXchange 5, no. 26 (June 2012): 668. http://dx.doi.org/10.1038/scibx.2012.668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 90, S2 (February 13, 2019): 120. http://dx.doi.org/10.1007/s00104-019-0845-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 88, no. 7 (June 14, 2017): 621. http://dx.doi.org/10.1007/s00104-017-0458-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Jain, Amit Kumar, Guruprasad Bhat, Vineet Govinda Gupta, and Hari Goyal. "Liquid Biopsy." Indian Journal of Medical and Paediatric Oncology 42, no. 01 (March 2021): 077–79. http://dx.doi.org/10.1055/s-0041-1729434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Liu, Yaoping, and Wei Wang. "Multi-Modal Microfluidics (M3) for Sample Preparation of Liquid Biopsy: Bridging the Gap between Proof-of-Concept Demonstrations and Practical Applications." Micromachines 13, no. 2 (January 28, 2022): 209. http://dx.doi.org/10.3390/mi13020209.

Full text

Abstract:

Liquid biopsy, the technique used to shed light on diseases via liquid samples, has displayed various advantages, including minimal invasiveness, low risk, and ease of multiple sampling for dynamic monitoring, and has drawn extensive attention from multidisciplinary fields in the past decade. With the rapid development of microfluidics, it has been possible to manipulate targets of interest including cells, microorganisms, and exosomes at a single number level, which dramatically promotes the characterization and analysis of disease-related markers, and thus improves the capability of liquid biopsy. However, when lab-ready techniques transfer into hospital-applicable tools, they still face a big challenge in processing raw clinical specimens, which are usually of a large volume and consist of rare targets drowned in complex backgrounds. Efforts toward the sample preparation of clinical specimens (i.e., recovering/concentrating the rare targets among complex backgrounds from large-volume liquids) are required to bridge the gap between the proof-of-concept demonstrations and practical applications. The throughput, sensitivity, and purity (TSP performance criteria) in sample preparation, i.e., the volume speed in processing liquid samples and the efficiencies of recovering rare targets and depleting the backgrounds, are three key factors requiring careful consideration when implementing microfluidic-based liquid biopsy for clinical practices. Platforms based on a single microfluidic module (single-modal microfluidics) can hardly fulfill all the aforementioned TSP performance criteria in clinical practices, which puts forward an urgent need to combine/couple multiple microfluidic modules into one working system (i.e., multi-modal microfluidics, M3) to realize practically applicable techniques for the sample preparation of liquid biopsy. This perspective briefly summarizes the typical microfluidic-based liquid biopsy techniques and discusses potential strategies to develop M3 systems for clinical practices of liquid biopsy from the aspect of sample preparation.

APA, Harvard, Vancouver, ISO, and other styles

13

Ruggero Errante, Paolo. "A New Era in the Management of Tumors in Dogs Based on Liquid Biopsy." International Journal of Zoology and Animal Biology 5, no. 2 (2022): 1–3. http://dx.doi.org/10.23880/izab-16000363.

Full text

Abstract:

The naturally occurring high-grade invasive transitional cell carcinoma or canine invasive urothelial carcinoma localized in bladder can be successfully treated surgically, however, at time of your diagnosis, it may present itself at an advanced stage, and distant metastases occur in 50% of cases. The urothelial carcinoma has a poor prognosis due to its muscle-invasive nature and high degree of metastases to regional lymph nodes or distant organs

APA, Harvard, Vancouver, ISO, and other styles

14

Ranuncolo, Stella Maris. "Liquid Biopsy in Liquid Tumors." Journal of Cancer Therapy 08, no. 03 (2017): 302–20. http://dx.doi.org/10.4236/jct.2017.83026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rossi, Davide, Valeria Spina, Alessio Bruscaggin, and Gianluca Gaidano. "Liquid biopsy in lymphoma." Haematologica 104, no. 4 (March 7, 2019): 648–52. http://dx.doi.org/10.3324/haematol.2018.206177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Trombetta, Domenico, Angelo Sparaneo, Federico Pio Fabrizio, and Lucia Anna Muscarella. "Liquid biopsy and NSCLC." Lung Cancer Management 5, no. 2 (June 2016): 91–104. http://dx.doi.org/10.2217/lmt-2016-0006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Wu, Lingling, Yidi Wang, Lin Zhu, Yilong Liu, Teng Wang, Dan Liu, Yanling Song, and Chaoyong Yang. "Aptamer-Based Liquid Biopsy." ACS Applied Bio Materials 3, no. 5 (February 11, 2020): 2743–64. http://dx.doi.org/10.1021/acsabm.9b01194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Poulet, Geoffroy, Joséphine Massias, and Valerie Taly. "Liquid Biopsy: General Concepts." Acta Cytologica 63, no. 6 (2019): 449–55. http://dx.doi.org/10.1159/000499337.

Full text

Abstract:

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents such as blood or urine instead of a fragment of cancer tissue. It is composed of different biological matrices such as circulating tumor cells (CTCs), cell free nucleic acids, exosomes or tumors “educated platelets.” In addition to representing a non- or minimally invasive procedure, it should represent a better view of tumor heterogeneity and allows for real-time monitoring of cancer evolution. Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progresses both in our ability to purify and analyze liquid biopsy components. In particular, the great developments of droplet-based digital PCR and the various optimizations of next generation sequencing technologies are central to the several validations of CTC-free DNA as a strong cancer biomarker. However, complete adoption of liquid biopsy in clinics will require pursuing recent efforts in the standardization of procedures both on the pre-analytical and analytical aspects.

APA, Harvard, Vancouver, ISO, and other styles

19

Wakelee, H. "PC 03.03 Liquid Biopsy." Journal of Thoracic Oncology 12, no. 11 (November 2017): S1666—S1667. http://dx.doi.org/10.1016/j.jtho.2017.09.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Stone, Louise. "Biomarkers from liquid biopsy." Nature Reviews Urology 13, no. 8 (July 19, 2016): 434. http://dx.doi.org/10.1038/nrurol.2016.133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Voelker, Rebecca. "Liquid Biopsy Receives Approval." JAMA 316, no. 3 (July 19, 2016): 260. http://dx.doi.org/10.1001/jama.2016.8833.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Harbour, J. William. "Liquid Biopsy in Retinoblastoma." JAMA Ophthalmology 135, no. 11 (November 1, 2017): 1231. http://dx.doi.org/10.1001/jamaophthalmol.2017.4094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

red. "Therapiekontrolle durch Liquid Biopsy." Info Onkologie 19, no. 8 (December 2016): 37. http://dx.doi.org/10.1007/s15004-016-5528-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Reimers, Natalie, Claudia Hille, and Klaus Pantel. "Aktuelles zur Liquid Biopsy." InFo Onkologie 21, S1 (June 2018): 24–29. http://dx.doi.org/10.1007/s15004-018-6134-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Salinas-Sánchez, A. S., C. Martínez-Sanchís, J. M. Giménez-Bachs, and D. C. García-Olmo. "Liquid biopsy in cancer." Actas Urológicas Españolas (English Edition) 40, no. 1 (January 2016): 1–2. http://dx.doi.org/10.1016/j.acuroe.2015.11.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Behrend, Christian. "Liquid Biopsy beim Kolonkarzinom." Im Focus Onkologie 21, no. 3 (March 2018): 15–16. http://dx.doi.org/10.1007/s15015-018-3816-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Banys-Paluchowski, Maggie, Natalia Krawczyk, and Tanja Fehm. "Liquid Biopsy beim Mammakarzinom." TumorDiagnostik & Therapie 42, no. 05 (May 31, 2021): 361–72. http://dx.doi.org/10.1055/a-1467-0165.

Full text

Abstract:

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

APA, Harvard, Vancouver, ISO, and other styles

28

Banys-Paluchowski, Maggie, Natalia Krawczyk, and Tanja Fehm. "Liquid Biopsy beim Mammakarzinom." Senologie - Zeitschrift für Mammadiagnostik und -therapie 18, no. 04 (December 2021): 365–76. http://dx.doi.org/10.1055/a-1678-1129.

Full text

Abstract:

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

APA, Harvard, Vancouver, ISO, and other styles

29

Ronvaux, Lorian, Matteo Riva, An Coosemans, Marielle Herzog, Guillaume Rommelaere, Nathalie Donis, Lionel D’Hondt, and Jonathan Douxfils. "Liquid Biopsy in Glioblastoma." Cancers 14, no. 14 (July 13, 2022): 3394. http://dx.doi.org/10.3390/cancers14143394.

Full text

Abstract:

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

APA, Harvard, Vancouver, ISO, and other styles

30

Burnus, Zygmunt, and Jarosław Markowski. "Zastosowanie chromatografii gazowej i cieczowej w badaniach produktów ciekłych pirolizy mikrofalowej." Nafta-Gaz 78, no. 1 (January 2022): 64–79. http://dx.doi.org/10.18668/ng.2022.01.07.

Full text

Abstract:

W niniejszej pracy zbadano możliwości wykorzystania technik chromatografii gazowej GC-FID oraz GC-MS wspomaganych klasyczną chromatografią cieczową LC do badania składników biooleju pochodzącego z pirolizy biomasy stałej. Badania biomasy i produktów jej przerobu mają na celu rozwój technologii paliw proekologicznych i/lub zawierających frakcje otrzymywane z biomasy lub surowców odpadowych. Celem tych działań jest stopniowe zwiększanie wykorzystania źródeł energii pochodzących z surowców odnawialnych przy jednoczesnym ograniczaniu zastosowania surowców kopalnych. Jest to jedno z działań, których efektem ma być ograniczenie emisji GHG. Działanie to jest związane z wytycznymi dyrektyw Unii Europejskiej nakazujących wzrost udziału odnawialnych źródeł energii w transporcie oraz energetyce. Są to dyrektywy 2003/30/WE oraz 2009/28/WE, dotyczące promowania użycia biopaliw lub innych paliw odnawialnych w transporcie oraz wzrostu udziału pozyskiwania energii ze źródeł odnawialnych w różnych sektorach krajów Wspólnoty Europejskiej. Energetyczne wykorzystanie biomasy to jeden z głównych obszarów zainteresowania polityki energetycznej Polski, zbieżnej z celami polityki wyznaczonymi przez Unię Europejską. W niniejszym artykule dokonano przeglądu literatury w zakresie rodzajów biomasy występującej w Polsce oraz zastosowania technik chromatografii gazowej i cieczowej (Py-GC, GC-MS, GC-FID) w badaniu ciekłych produktów procesu pirolizy biomasy. Opracowano warunki chromatograficzne badania produktów ciekłych pirolizy biomasy stałej przy wykorzystaniu reaktora mikrofalowego do pirolizy jako elementu aparatury umożliwiającego badania technikami chromatograficznymi. Przy zastosowaniu dobranych warunków analitycznych wykonano badania ciekłych produktów pirolizy biomasy: miskantu olbrzymiego, słomy, trocin sosnowych, łusek słonecznika i ziaren kawy. Zidentyfikowano składniki biooleju pochodzącego z pirolizy biomasy i zaproponowano metodę oznaczania ilościowego składników biooleju. Wykazano możliwość jednoczesnego zastosowania różnych technik chromatografii gazowej w celu poznania składu chemicznego biooleju pochodzącego z pirolizy mikrofalowej różnego rodzaju biomasy stałej.

APA, Harvard, Vancouver, ISO, and other styles

31

Ilié, Marius, and Paul Hofman. "Pros: Can tissue biopsy be replaced by liquid biopsy?" Translational Lung Cancer Research 5, no. 4 (August 2016): 420–23. http://dx.doi.org/10.21037/tlcr.2016.08.06.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Corcoran, Ryan B. "Liquid biopsy versus tumor biopsy for clinical-trial recruitment." Nature Medicine 26, no. 12 (November 23, 2020): 1815–16. http://dx.doi.org/10.1038/s41591-020-01169-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Keup, Corinna, Rainer Kimmig, and Sabine Kasimir-Bauer. "Combinatorial Power of cfDNA, CTCs and EVs in Oncology." Diagnostics 12, no. 4 (March 31, 2022): 870. http://dx.doi.org/10.3390/diagnostics12040870.

Full text

Abstract:

Liquid biopsy is a promising technique for clinical management of oncological patients. The diversity of analytes circulating in the blood useable for liquid biopsy testing is enormous. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and extracellular vesicles (EVs), as well as blood cells and other soluble components in the plasma, were shown as liquid biopsy analytes. A few studies directly comparing two liquid biopsy analytes showed a benefit of one analyte over the other, while most authors concluded the benefit of the additional analyte. Only three years ago, the first studies to examine the value of a characterization of more than two liquid biopsy analytes from the same sample were conducted. We attempt to reflect on the recent development of multimodal liquid biopsy testing in this review. Although the analytes and clinical purposes of the published multimodal studies differed significantly, the additive value of the analytes was concluded in almost all projects. Thus, the blood components, as liquid biopsy reservoirs, are complementary rather than competitive, and orthogonal data sets were even shown to harbor synergistic effects. The unmistakable potential of multimodal liquid biopsy testing, however, is dampened by its clinical utility, which is yet to be proven, the lack of methodical standardization and insufficiently mature reimbursement, logistics and data handling.

APA, Harvard, Vancouver, ISO, and other styles

34

Junker, Kerstin. "Liquid biopsy zur Individualisierung der Therapie beim fortgeschrittenen Harnblasenkarzinom." Aktuelle Urologie 53, no. 02 (December 7, 2021): 180–87. http://dx.doi.org/10.1055/a-1646-9568.

Full text

Abstract:

ZusammenfassungDie Analyse von Körperflüssigkeiten („Liquid biopsy“), rückt zunehmend in den Fokus der Biomarkerentwicklung, da sie entscheidende Vorteile gegenüber der Gewebeanalyse aufweist. In den Körperflüssigkeiten können neben Proteinen und Lipoproteinen auch zirkulierende Tumorzellen (CTCs), extrazelluläre Vesikel (EVs) sowie deren Bestandteile und zellfreie Nukleinsäuren (DNA, RNA) analysiert werden. Muskelinvasive Harnblasentumore (MIHB) stellen eine besondere klinische Herausforderung dar. Hier werden neue Biomarker benötigt, um das individuelle Metastasierungsrisiko einzuschätzen, die Metastasierung im Follow-up frühzeitig zu erkennen und die effektivste systemische Therapie für den einzelnen Patienten einzusetzen. Diese Arbeit gibt einen Überblick über den aktuellen Stand zur „Liquid Biospy“ aus dem Blut bei fortgeschrittenen MIHB unter Berücksichtigung von CTCs, zirkulierender Tumor-DNA (ctDNA), nicht kodierenden RNAs (ncRNAs) sowie EVs und deren Bedeutung für Prognosebewertung und Therapieentscheidung.

APA, Harvard, Vancouver, ISO, and other styles

35

Saini, Aman, Yash Pershad, Hassan Albadawi, Malia Kuo, Sadeer Alzubaidi, Sailendra Naidu, M.-Grace Knuttinen, and Rahmi Oklu. "Liquid Biopsy in Gastrointestinal Cancers." Diagnostics 8, no. 4 (October 29, 2018): 75. http://dx.doi.org/10.3390/diagnostics8040075.

Full text

Abstract:

Liquid biopsy is the sampling of any biological fluid in an effort to enrich and analyze a tumor’s genetic material. Peripheral blood remains the most studied liquid biopsy material, with circulating tumor cells (CTC’s) and circulating tumor DNA (ctDNA) allowing the examination and longitudinal monitoring of a tumors genetic landscape. With applications in cancer screening, prognostic stratification, therapy selection and disease surveillance, liquid biopsy represents an exciting new paradigm in the field of cancer diagnostics and offers a less invasive and more comprehensive alternative to conventional tissue biopsy. Here, we examine liquid biopsies in gastrointestinal cancers, specifically colorectal, gastric, and pancreatic cancers, with an emphasis on applications in diagnostics, prognostics and therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

36

Kim, In Ae, Jae Young Hur, Hee Joung Kim, Wan Seop Kim, and Kye Young Lee. "Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC." Cancers 14, no. 11 (May 31, 2022): 2744. http://dx.doi.org/10.3390/cancers14112744.

Full text

Abstract:

To overcome the limitations of the tissue biopsy and plasma cfDNA liquid biopsy, we performed the EV-based BALF liquid biopsy of 224 newly diagnosed stage III-IV NSCLC patients and compared it with tissue genotyping and 110 plasma liquid biopsies. Isolation of EVs from BALF was performed by ultracentrifugation. EGFR genotyping was performed through peptide nucleic acid clamping-assisted fluorescence melting curve analysis. Compared with tissue-based genotyping, BALF liquid biopsy demonstrated a sensitivity, specificity, and concordance rates of 97.8%, 96.9%, and 97.7%, respectively. The performance of BALF liquid biopsy was almost identical to that of standard tissue-based genotyping. In contrast, plasma cfDNA-based liquid biopsy (n = 110) demonstrated sensitivity, specificity, and concordance rates of 48.5%, 86.3%, and 63.6%, respectively. The mean turn-around time of BALF liquid biopsy was significantly shorter (2.6 days) than that of tissue-based genotyping (13.9 days; p < 0.001). Therefore, the use of EV-based BALF shortens the time for confirmation of EGFR mutation status for starting EGFR-TKI treatment and can hence potentially improve clinical outcomes. As a result, we suggest that EV-based BALF EGFR testing in advanced lung NSCLC is a highly accurate rapid method and can be used as an alternative method for lung tissue biopsy.

APA, Harvard, Vancouver, ISO, and other styles

37

Nowosh, Victor, and Cristina de O. M. S. Gomes. "Liquid biopsy and its applications in veterinary medicine – a review." Clínica Veterinária XXIV, no. 139 (March 1, 2019): 36–52. http://dx.doi.org/10.46958/rcv.2019.xxiv.n.139.p.36-52.

Full text

Abstract:

Liquid biopsy is a diagnostic and prognostic tool already reported in several studies with human oncologic patients, and shows potential for application in veterinary oncology. However, liquid biopsy is not a widely known technique in veterinary medicine, and related research is sparse. Liquid biopsy is based on the analysis of blood samples for detection of various tumoral products in circulation. It is a non-invasive technique, and provides results in real time. Information obtained from liquid biopsies can complement the information obtained from the analysis of tissue biopsy. In this review of literature, we present the background principles of liquid biopsy, its methodology, and the tumoral products that can currently be detected with this tool. In addition to circulating tumor cells, liquid biopsies allow detection of nucleic acids, including tumor DNA, micro-RNA, messenger RNA and exosomes. We present the value of liquid biopsy as a diagnostic and prognostic tool, its predictive value in tumor progression and treatment success, and usefulness to assist treatment choice. We discuss its limitations, and the challenges to implement its use in a large scale.

APA, Harvard, Vancouver, ISO, and other styles

38

Aghamir, Seyed Mohammad Kazem, Ramin Heshmat, Mehdi Ebrahimi, and Fatemeh Khatami. "Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors." Epigenetics Insights 13 (January 2020): 251686572090405. http://dx.doi.org/10.1177/2516865720904052.

Full text

Abstract:

Blood test is a kind of liquid biopsy that checks cancer cells or cancer nucleic acids circulating freely from cells in the blood. A liquid biopsy may be used to distinguish cancer at early stages and it could be a game-changer for both cancer diagnosis and prognosis strategies. Liquid biopsy tests consider several tumor components, such as DNA, RNA, proteins, and the tiny vesicles originating from tumor cells. Actually, liquid biopsy signifies the genetic alterations of tumors through nucleic acids or cells in various body fluids, including blood, urine, cerebrospinal fluid, or saliva in a noninvasive manner. In this review, we present an overall description of liquid biopsy in which circulating tumor cells, cell-free nucleic acids, exosomes, and extrachromosomal circular DNA are included.

APA, Harvard, Vancouver, ISO, and other styles

39

Lissa, Delphine, and Ana I. Robles. "Methylation analyses in liquid biopsy." Translational Lung Cancer Research 5, no. 5 (October 2016): 492–504. http://dx.doi.org/10.21037/tlcr.2016.10.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

AKIN KABALAK, Pinar, and Ulku YILMAZ. "Liquid Biopsy in Lung Cancer." Güncel Göğüs Hastalıkları Serisi 6, no. 3 (August 4, 2020): 18–22. http://dx.doi.org/10.5152/gghs.2018.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Santise, G., D. Maselli, C. Mignogna, K. PIrrone, V. Mollace, G. Donato, and N. Malara. "RF41 LIQUID BIOPSY FORCARDIAC TUMORS." Journal of Cardiovascular Medicine 19 (November 2018): e77. http://dx.doi.org/10.2459/01.jcm.0000550086.27815.c2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lousada-Fernandez, Fatima, Oscar Rapado-Gonzalez, Jose-Luis Lopez-Cedrun, Rafael Lopez-Lopez, Laura Muinelo-Romay, and Maria Suarez-Cunqueiro. "Liquid Biopsy in Oral Cancer." International Journal of Molecular Sciences 19, no. 6 (June 8, 2018): 1704. http://dx.doi.org/10.3390/ijms19061704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ueda, Koji. "Cancer liquid biopsy using exosomes." Electrophoresis Letters 61, no. 2 (2017): 65–68. http://dx.doi.org/10.2198/electroph.61.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ranade, A. A., A. Bhatt, Darshana Patil, Indu Patwal, D. B. Akolkar, D. A. Joshi, P. P. Patil, R. R. Dasare, T. D. Bhangale, and Y. R. Jha. "Liquid biopsy in periampullary carcinoma." International Journal of Molecular and Immuno Oncology 1, no. 1 (November 25, 2016): 45. http://dx.doi.org/10.18203/issn.2456-3994.intjmolimmunooncol20164388.

Full text

Abstract:

<p style="margin: 0in 0in 8pt 0.25in; text-align: justify;">Periampullary cancers are rare tumors arising within 2 cm of the major papilla of the duodenum. In this case report, we describe the use of liquid biopsy to analyze cell-free tumor DNA and exosomal microRNA to guide treatment selection in a patient with periampullary adenocarcinoma. To our knowledge, this is the first time such case report has been described in the literature.</p>

APA, Harvard, Vancouver, ISO, and other styles

45

Sahoo, TapanKumar. "Liquid biopsy in oncology practice." Oncology Journal of India 2, no. 3 (2018): 45. http://dx.doi.org/10.4103/oji.oji_32_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Zmarzły, Nikola, Ewelina Hermyt, Andrzej Witek, Joanna Gola, and Urszula Mazurek. "Liquid biopsy in endometrial cancer." Current Gynecologic Oncology 17, no. 1 (July 31, 2019): 27–42. http://dx.doi.org/10.15557/cgo.2019.0004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Pantel, Klaus, and Catherine Alix-Panabières. "Liquid biopsy: Potential and challenges." Molecular Oncology 10, no. 3 (February 1, 2016): 371–73. http://dx.doi.org/10.1016/j.molonc.2016.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Biswas, Dhruva, Jane Ganeshalingam, and Jonathan C. M. Wan. "The future of liquid biopsy." Lancet Oncology 21, no. 12 (December 2020): e550. http://dx.doi.org/10.1016/s1470-2045(20)30687-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Haupts, A., W. Roth, and N. Hartmann. "Liquid Biopsy im kolorektalen Karzinom." Der Pathologe 40, S3 (December 2019): 244–51. http://dx.doi.org/10.1007/s00292-019-00698-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lehmann, U., and S. Bartels. "Liquid Biopsy in der Tumordiagnostik." Der Pathologe 40, no. 3 (May 2019): 250–55. http://dx.doi.org/10.1007/s00292-019-0604-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!